Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes

Antiviral Research

Volumn 69, Issue 3, 2006, Pages 165-172

  Gowen, Brian B ^a   Fairman, Jeff ^b   Smee, Donald F ^a   Wong, Min Hui ^a   Jung, Kie Hoon ^a   Pace, Anne M ^a   Heiner, Matthew L ^a   Bailey, Kevin W ^a   Dow, Steven W ^c   Sidwell, Robert W ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b Juvaris BioTherapeutics Inc   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Innate immunity; Liposome; Phlebovirus; Plasmid DNA

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CATION; CATIONIC LIPOSOME DNA COMPLEX; CYTOKINE; GAMMA INTERFERON; IMMUNOSTIMULATING AGENT; INTERLEUKIN 12; LIPOSOME; OCTADECENOYLOXY(ETHYL 2 HEPTADECENYL 3 HYDROXYETHYL)IMIDAZOLIUM CHLORIDE; PLASMID DNA; RIBAVIRIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHRONOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; IMMUNOSTIMULATION; IMMUNOTHERAPY; MORTALITY; MOUSE; NONHUMAN; PHLEBOVIRUS; PHLEBOVIRUS INFECTION; PRIORITY JOURNAL; PROVOCATION TEST; PUNTA TORO VIRUS; SURVIVAL; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BUNYAVIRIDAE INFECTIONS; CYTOKINES; DNA, VIRAL; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LIPOSOMES; LIVER; MICE; PHLEBOVIRUS; SURVIVAL ANALYSIS; VIRAL LOAD;

ANIMALIA; PERU TOMATO MOSAIC VIRUS; PHLEBOVIRUS; PUNTA TORO VIRUS;

EID: 32644463737     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2005.12.002     Document Type: Article

References (20)

1. K. Ahmad More deaths from Rift Valley fever in Saudi Arabia and Yemen Lancet 356 2000 1422
2. Centers for Disease Control and Prevention (CDC), 1994. Rift Valley fever-Egypt - 1993. MMWR. Morb. Mortal. Wkly. Rep. 43, 693, 699-700.
3. S.W. Dow, L.G. Fradkin, D.H. Liggitt, A.P. Willson, T.D. Heath, and T.A. Potter Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously J. Immunol. 163 1999 1552 1561
4. S.W. Dow, J. Schwarze, T.D. Heath, T.A. Potter, and E.W. Gelfand Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice Hum. Gene Ther. 10 1999 1905 1914
5. B.D. Freimark, H.P. Blezinger, V.J. Florack, J.L. Nordstrom, S.D. Long, D.S. Deshpande, S. Nochumson, and K.L. Petrak Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes J. Immunol. 160 1998 4580 4586
6. I. Gursel, M. Gursel, K.J. Ishii, and D.M. Klinman Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides J. Immunol. 167 2001 3324 3328
7. H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira A Toll-like receptor recognizes bacterial DNA Nature 408 2000 740 745
8. A.M. Krieg CpG motifs in bacterial DNA and their immune effects Annu. Rev. Immunol. 20 2002 709 760
9. J.M. Meegan The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizootic and virological studies Trans. Roy. Soc. Trop. Med. Hyg. 73 1979 618 623
10. National Institute of Allergy and Infectious Diseases (NIAID), 2002. The Counter-Bioterrorism Research Agenda of the National Institute of Allergy and Infectious Diseases (NIAID) for CDC Category A Agents. National Institutes of Health, Bethesda, MD.
11. D.Y. Pifat, and J.F. Smith Punta Toro virus infection of C57BL/6J mice: a model for phlebovirus-induced disease Microb. Pathogenesis 3 1987 409 422
12. L.J. Reed, and H. Muench A simple method of estimating fifty percent endpoints Am. J. Hyg. 27 1938 493 497
13. L. Romani, P. Puccetti, and F. Bistoni Interleukin-12 in infectious diseases Clin. Microbiol. Rev. 10 1997 611 636
14. C.E. Samuel Antiviral actions of interferons Clin. Microbiol. Rev. 14 2001 778 809
15. K. Sellins, L. Fradkin, D. Liggitt, and S. Dow Type I interferons potently suppress gene expression following gene delivery using liposome(-)DNA complexes Mol. Ther. 12 2005 451 459
16. R.W. Sidwell, J.H. Huffman, D.L. Barnard, D.F. Smee, R.P. Warren, M.A. Chirigos, M. Kende, and J. Huggins Antiviral and immunomodulating inhibitors of experimentally-induced Punta Toro virus infections Antiviral Res. 25 1994 105 122
17. R.W. Sidwell, J.H. Huffman, B.B. Barnett, and D.Y. Pifat In vitro and in vivo Phlebovirus inhibition by ribavirin Antimicrob. Agents Chemother. 32 1988 331 336
18. R.W. Sidwell, J.H. Huffman, D.F. Smee, J. Gilbert, A. Gessamen, A. Pease, R.P. Warren, J. Huggins, and M. Kende Potential role of immunomodulators for treatment of phlebovirus infections of animals Ann. NY Acad. Sci. 653 1992 344 355
19. D.F. Smee, J.H. Huffman, A.C. Gessaman, J.W. Huggins, and R.W. Sidwell Prophylactic and therapeutic activities of 7-thia-8-oxoguanosine against Punta Toro virus infections in mice Antiviral Res. 15 1991 229 239
20. N. Zhu, D. Liggitt, Y. Liu, and R. Debs Systemic gene expression after intravenous DNA delivery into adult mice Science 261 1993 209 211